Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
The plan is to advance innovative therapies to drug-resistant cancers
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The report has estimated 4.74 million deaths for India in 2020 and 2021,
Subscribe To Our Newsletter & Stay Updated
